Risk factors and outcomes associated with the isolation of polymyxin B and carbapenem-resistant Enterobacteriaceae spp.: A case-control study
- PMID: 30880229
- DOI: 10.1016/j.ijantimicag.2019.03.011
Risk factors and outcomes associated with the isolation of polymyxin B and carbapenem-resistant Enterobacteriaceae spp.: A case-control study
Abstract
Increasing resistance to polymyxin, a last-line antibiotic, is a growing public health concern worldwide. The primary objective of this study was to identify predictors for the isolation of polymyxin-resistant (PR) carbapenem-resistant Enterobacteriaceae (CRE) among hospitalized patients. The secondary objective was to describe the clinical outcomes of patients with PR-CRE infections. A retrospective case-control study including patients admitted to Singapore General Hospital between June 2012 and June 2016 was conducted. Cases were defined as patients who had clinical cultures from which a PR-CRE was isolated. Controls were randomly selected from patients with polymyxin-susceptible (PS) CRE admitted during the same period, and frequency-matched to site of isolation. We included 37 PR cases and 111 PS controls. Polymyxin resistance was detected predominantly in Enterobacter spp. (54.1%) and Klebsiella pneumoniae (43.2%). Multilocus sequence typing showed little clonal relatedness among the isolates. mcr-1 was detected in two PR-CRE isolates. Multivariable analyses showed that PR-CRE isolation was associated with prior polymyxins (adjusted odds ratio (OR), 21.31; 95% confidence interval (CI), 3.04-150.96) and carbapenem exposures (OR 3.74; CI 1.13-12.44), when adjusted for time at risk and bacteria species. In PR-CRE patients with infections, the 30-day all-cause in-hospital mortality was 50.0% as compared to 38.1% in patients with PS-CRE (P = 0.346). Prior polymyxin and carbapenem exposures were independent risk factors for isolation of PR-CRE. Outcomes of PR-CRE and PS-CRE infections were similar in this study.
Keywords: Colistin; Enterobacteriaceae; Polymyxin; Predictors; Resistance.
Copyright © 2019 Elsevier Ltd. All rights reserved.
Similar articles
-
Polymyxin resistance in carbapenem-resistant Enterobacteriaceae isolates from patients without polymyxin exposure: a multicentre study in China.Int J Antimicrob Agents. 2021 Feb;57(2):106262. doi: 10.1016/j.ijantimicag.2020.106262. Epub 2020 Dec 23. Int J Antimicrob Agents. 2021. PMID: 33347990
-
The role of therapy with aminoglycoside in the outcomes of kidney transplant recipients infected with polymyxin- and carbapenem-resistant Enterobacteriaceae.Eur J Clin Microbiol Infect Dis. 2019 Apr;38(4):755-765. doi: 10.1007/s10096-019-03468-4. Epub 2019 Jan 24. Eur J Clin Microbiol Infect Dis. 2019. PMID: 30680569
-
Post-surgical mediastinitis due to carbapenem-resistant Enterobacteriaceae: Clinical, epidemiological and survival characteristics.Int J Antimicrob Agents. 2016 May;47(5):386-90. doi: 10.1016/j.ijantimicag.2016.02.015. Epub 2016 Apr 6. Int J Antimicrob Agents. 2016. PMID: 27155944
-
Carbapenem and colistin resistance in Enterobacteriaceae in Southeast Asia: Review and mapping of emerging and overlapping challenges.Int J Antimicrob Agents. 2019 Oct;54(4):381-399. doi: 10.1016/j.ijantimicag.2019.07.019. Epub 2019 Jul 29. Int J Antimicrob Agents. 2019. PMID: 31369812
-
Carbapenem-Resistant Enterobacteriaceae: An update narrative review from Saudi Arabia.J Infect Public Health. 2019 Jul-Aug;12(4):465-471. doi: 10.1016/j.jiph.2019.03.024. Epub 2019 May 3. J Infect Public Health. 2019. PMID: 31060974 Review.
Cited by
-
Risk Factors and Outcomes for Isolation with Polymyxin B-Resistant Enterobacterales from 2018-2022: A Case-Control Study.Infect Drug Resist. 2023 Dec 22;16:7809-7817. doi: 10.2147/IDR.S435697. eCollection 2023. Infect Drug Resist. 2023. PMID: 38148770 Free PMC article.
-
Risk Factors and Prognosis of Polymyxin- and Carbapenem-Resistant Enterobacteriaceae Infections: A Propensity-Matched Real-World Study.Microorganisms. 2025 May 29;13(6):1256. doi: 10.3390/microorganisms13061256. Microorganisms. 2025. PMID: 40572145 Free PMC article.
-
Clinical outcomes and safety of polymyxin B versus tigecycline combination therapy for pneumonia of carbapenem-resistant Klebsiella pneumoniae: a retrospective cohort study.Ann Med. 2024 Dec;56(1):2397087. doi: 10.1080/07853890.2024.2397087. Epub 2024 Sep 6. Ann Med. 2024. PMID: 39239861 Free PMC article.
-
Next-Generation Polymyxin Class of Antibiotics: A Ray of Hope Illuminating a Dark Road.Antibiotics (Basel). 2022 Nov 27;11(12):1711. doi: 10.3390/antibiotics11121711. Antibiotics (Basel). 2022. PMID: 36551367 Free PMC article. Review.
-
Global colistin use: a review of the emergence of resistant Enterobacterales and the impact on their genetic basis.FEMS Microbiol Rev. 2022 Feb 9;46(1):fuab049. doi: 10.1093/femsre/fuab049. FEMS Microbiol Rev. 2022. PMID: 34612488 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous